Article

How Exchange Market Size Matters

It's an incorrect, but convenient, shorthand to say that the Affordable Care Act establishes state-based health insurance markets. Actually, the markets are finer grained than that.

It’s an incorrect, but convenient, shorthand to say that the Affordable Care Act establishes state-based health insurance markets. Actually, the markets are finer grained than that. Each state can decide the number and configuration of coverage regions that will exist within its borders, and insurers must elect whether to offer plans on a region-by-region basis. Across a region, for a given plan, premiums and benefits are fixed.

These within-state regions are the real markets. Do their sizes and configurations matter?

According to work by Michael Dickstein and colleagues, released in an NBER working paper, they do. This is intuitive. If there is some fixed cost of entry that’s largely independent of the number of potential consumers (market size), then an insurer should be more willing to enter a bigger market vs. a smaller one. (Such fixed costs could include those for marketing or for customer service centers, for instance.) Maybe bigger markets are better for competition and consumers.

Read more at AcademyHealth: http://bit.ly/1cAbSDO

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Related Videos
Merrill H. Stewart, MD
Andrew Evens, DO, MBA, MSc, deputy director for clinical services and chief physician officer, Rutgers Cancer Institute and Jack & Sheryl Morris Cancer Center
Constance Blunt, MD, medical oncologist, Mary Bird Perkins Cancer Center
Merrill H. Stewart, MD
H. John Beardsley, MBA, and Fauzea Hussain, MPH, sitting for a video interview
Constance Blunt, MD, medical oncologist, Mary Bird Perkins Cancer Center
Merrill H. Stewart, MD
Dr CK Wang
Nini Wu, MD, Navista
Jonathan Strober, MD, UCSF Benioff Children's Hospital
Related Content
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo